Status:
COMPLETED
Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
BioTex, Inc.
Conditions:
Advanced Cancer
Bone Metastases
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal of this clinical research study is to learn how well magnetic resonance thermal imaging (MRTI) can check the amount of tumor being destroyed using a therapy called laser ablation (a procedure...
Detailed Description
Laser ablation is designed to destroy tumor tissue with the use of fiber optics that are placed directly into the tumor to deliver laser light energy into the tissue. In this study, tumor destruction...
Eligibility Criteria
Inclusion
- Patients with tumor metastases to the skeleton who are referred to interventional radiology for percutaneous ablation
- Surgery is not a viable or desirable alternative therapy at the time of enrollment
- Radiation therapy has failed or not indicated or can be safely postponed
- Symptomatic or asymptomatic tumor size less than or equal to 3 cm in its largest diameter.
- Performance status is Eastern Cooperative Oncology Group 2 or better in adults
- Patient is able to undergo MRI
- Patients at least 18 years of age
Exclusion
- Patients with uncorrectable coagulopathy
- Patients with pacemaker or defibrillator
- Patients with metallic prosthesis at the site of the intended ablation
- Patients with spinal cord compression or epidural tumor extension
- Patients with vertebral body metastases exhibiting posterior wall destruction
- Patients with any soft tissue extension of a vertebral tumor
- Patients with any metastasis that is extrinsically located in vertebra or any long bones of the extremities compromising the cortex
- Patients with tumors having direct extension or involvement of a joint capsule or a major nerve
- Patients with Neutropenia (ANC less then 1000) or known active infection
- Patients unable to undergo conscious sedation
- Children under 18 years of age will be excluded from this study
Key Trial Info
Start Date :
May 13 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 12 2017
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00688038
Start Date
May 13 2008
End Date
September 12 2017
Last Update
September 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030